Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer
Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer
复制标题
DOI：
10.1016/s0090-4295(02)01566-2
复制
发表时间：
2002-09-01
期刊：
影响因子：
2.1
通讯作者：
D'Amico, AV
中科院分区：
文献类型：
--
作者：
D'Amico, AV
局部晚期前列腺癌（TNM临床分期T3、T4）患者接受外束放疗（EBRT）和3年雄激素剥夺治疗（ADT）与单独接受EBRT治疗的患者进行比较，结果显示生存获益。针对临床局限性疾病（T1、T2期）患者的相同问题的研究已经完成，正在等待随访研究。在新辅助ADT的第一个月期间，血清血红蛋白水平下降率大于或等于1 g/dL，根据前列腺特异性抗原的定义，对于接受EBRT和ADT的中度和高风险临床局部疾病患者，预测无病生存结果显着恶化。需要其他人对这一预测因素进行验证。
Patients with locally advanced prostate cancer (TNM clinical stage T3, T4) who were treated using external-beam radiotherapy (EBRT) and 3 years of androgen deprivation therapy (ADT) were compared with patients treated with EBRT alone and were shown to have a survival benefit. Studies that address the same question for patients with clinically localized disease (stage T1, T2) have been completed and are awaiting follow-up study. A rate of decrease in the serum hemoglobin level of greater than or equal to1 g/dL during the first month of neoadjuvant ADT predicted for a significantly worse disease-free survival outcome, as defined by the prostate-specific antigen, for patients with intermediate- and high-risk clinically localized disease who were undergoing EBRT and ADT. Validation of this predictive factor by others is needed.